India, Aug. 17 -- India's pharmaceutical industry continues to see the growth in specialised complex injectables and contract manufacturing, while companies are also looking to expand their presence in international markets. Gufic Biosciences delivered a strong start to FY27, with profit growing much faster than revenue. The company is also continuing to scale its manufacturing capabilities and build a pipeline of differentiated products, which could support growth in the coming years.

Gufic Bioscience shares closed at Rs. 418.20 down by 0.79% and the opening was Rs. 400.20. The company's 52 week low was Rs. 268 and 52 week high is Rs. 432.35. The company's market capitalization Rs. 4,202.84 Cr.and its current P/E ratio is 56.74.

Gufic ...